Latest Nike Spikes

Acid Extractable Matrix Spikes

CLPS-MSA15-TI 1ML
EUR 52.8

Human IgG antibody Laboratories manufactures the latest nike spikes reagents distributed by Genprice. The Latest Nike Spikes reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike S. Other Latest products are available in stock. Specificity: Latest Category: Nike Group: Spikes

True north Cryobox 15mLNatural

PK10
EUR 212.4

True north Cryobox 15mLBlue

PK10
EUR 212.4

True north Cryobox 50mLNatural

PK10
EUR 210

True north Cryobox 50mLBlue

PK10
EUR 210

True north Cryobox1.5/2mLNatural

PK10
EUR 162

True north Cryobox1.5/2.0mLGreen

PK10
EUR 162

Human true insulin,TI ELISA Kit

96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Spikes information

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)

100678-2 1 mg
EUR 3000
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)

100719-1 100 µg
EUR 320
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)

100719-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody

9685-002mg 0.02 mg
EUR 229.7
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.

SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody

9685-01mg 0.1 mg
EUR 594.26
Description: SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)

100992-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)

100992-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

100731-1 20 µg
EUR 310
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™.

Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

100731-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™.

Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2)

100679-1 20 µg
EUR 305
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2)

100679-2 50 µg
EUR 450
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2)

100720-1 25 µg
EUR 295
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2)

100720-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation.

SARS-CoV-2 (COVID-19) Spike 681P Antibody

9091-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).